Ascentage and Henlius to Test Two-drug Combination in China Leukemia Trial

Suzhou's Ascentage Pharma will collaborate with Henlius of Shanghai on a China trial that combines Ascentage's Bcl-2 inhibitor with Henlius' Rituxan (rituximab) biosimilar in patients with chronic lymphocytic leukemia (CLL). Ascentage's APG-2575 is the first China-developed Bcl-2 inhibitor to begin clinical trials, while Henlius' rituximab injection is the first China biosimilar approved for use. APG-2575 blocks Bcl-2 to restore apoptosis in hematologic cancers. Henlius' biosimilar is approved to treat CLL in China. One week ago, Ascentage completed its Hong Kong IPO, while Henlius staged a Hong Kong IPO in September. More details.... Stock Symbols: (HK: 6855) (HK: 2696) Share this with colleagues: // //